Clinical trials: Empagliflozin
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin + Linagliptin 25 mg/5 mg Film-coated Tablets Versus Glyxambi 25 mg/ 5 mg Film-coated Tablets
An open label, balanced, randomized, single dose, two treatment, two sequence, two period, two way crossover oral bioequivalence study in healthy, adult, human subjects under fasting condition.
- Trial name
- NCT06932159
- Testing
- Empagliflozin + Linagliptin film-coated tablets, Glyxambi film-coated tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Diabetes Mellitus, Type 2
DIA_CENTRAL:T2D Treatment Pattern in Central Europe
This is a non-interventional study using existing data including medical chart review.
- Trial name
- NCT03807440
- Testing
- Empagliflozin, Sodium Glucose Transporter 2 inhibitor, Dipeptidyl-peptidase 4 inhibitor
- Where
- 177 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 4,083 people
- Sponsor
- Boehringer Ingelheim
Healthy
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing empagliflozin \& metformin and the single tablets of empagliflozin and metformin when…
- Trial name
- NCT01975220
- Testing
- Empagliflozin/Metformin XR, FDC, Empagliflozin/Metformin XR FDC, 25 mg Empagliflozin/1000 mg Metformin XR, FDC
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Renal Insufficiency, Chronic
Efficacy and Safety of Metformin Versus Empagliflozin on Chronic Kidney Disease Progression
This randomized controlled trial aims at evaluating the efficacy and safety of the antidiabetics metformin versus empagliflozin on chronic kidney disease (CKD) progression in patients with CKD stages 2 or/and 3.
- Trial name
- NCT05373680
- Testing
- Metformin, Empagliflozin, Control
- Where
- 2 sites in Egypt
- Volunteers
- 118 people
- Sponsor
- Tanta University
Myocardial Infarction
EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)
This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart…
- Trial name
- NCT04509674
- Testing
- Empagliflozin
- Where
- 439 sites in United States, Argentina and 20 more
- Volunteers
- 6,522 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus (T2DM)
To Compare and Evaluate the Oral Bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg Filmcoated Tablets With That of Glyxambi 10 mg/ 5 mg Film-coated Tablets in Healthy, Adult, Human Subjects Under Fasting Conditions.
To compare and evaluate the oral bioavailability of Empagliflozin + Linagliptin 10 mg/5 mg film-coated tablets with that of Glyxambi 10 mg/ 5 mg film-coated tablets in healthy, adult, human subjects under fasting conditions.
- Trial name
- NCT07039890
- Testing
- Empagliflozin + Linagliptin filmcoated tablets, Glyxambi film-coated tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Diabetes Mellitus, Type 2
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control.
- Trial name
- NCT01649297
- Testing
- empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid)
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Heart Failure With Reduced Ejection Fraction
HF Patients With LVADs Being Treated With SGLT2i
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
- Trial name
- NCT05278962
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Bioequivalance
Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions
Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study
- Trial name
- EB-24-003 (NCT07479108)
- Testing
- Empagliflozin (Jardiance®), Empagliflozin (oral)
- Where
- Mexico
- Volunteers
- 32 people
- Sponsor
- ADIUM
Diabetes Mellitus, Renal Insufficiency
Empagliflozin in Renal Transplant Recipients
This is a single-center, prospective, controlled, double-blind, randomized study. A total of 50 renal transplant recipients diagnosed with post-transplantation diabetes mellitus (PTDM) will be included more than 1 year after…
- Conditions
- Diabetes Mellitus, Renal Insufficiency, Safety Issues
- Trial name
- EMPA-RenalTx (NCT03157414)
- Testing
- Empagliflozin
- Where
- Norway
- Volunteers
- 49 people
- Sponsor
- Oslo University Hospital
Diabete Type 2
Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
- Trial name
- EMPAGO (NCT07365358)
- Testing
- empagliflozin 10mg, Glimepiride 1mg
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes Mellitus (T2DM)
Bioequivalence Study to Compare Empagliflozin/ Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg
An open label, randomized, two-period, two treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study to compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet versus Synjardy XR tablets…
- Trial name
- NCT07694115
- Testing
- Empagliflozin / Metformin Extended-Release Tablet, Synjardy XR tablets
- Where
- India
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Humanis Saglık Anonim Sirketi
Healthy
Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects
To investigate the pharmacokinetics of the test and the reference preparation Empagliflozin And Linagliptin Tablets in healthy adult subjects by single oral administration in fasting/postprandial state, and to evaluate the…
- Trial name
- NCT05956522
- Testing
- Test Empagliflozin And Linagliptin Tablets, Reference Empagliflozin And Linagliptin tablets
- Where
- China
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- The Affiliated Hospital of Qingdao University
Heart Failure With Preserved Ejection Fraction
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
This study will test whether pharmacologic agents that may improve mitochondrial function and energy fuel metabolism [Empagliflozin (Empa)], with and without additional supplements that increase perfusion and fatty acid oxidation…
- Trial name
- SAK (NCT05138575)
- Testing
- Empagliflozin + Potassium Chloride, Empagliflozin + Potassium Nitrate
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Pennsylvania
Type 2 Diabetes
Characteristics of Empagliflozin Initiators
Empagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, was launched in the United Kingdom (UK) in August 2014. It can be expected that patients initiating empagliflozin may differ in their characteristics from…
- Trial name
- NCT03050619
- Testing
- Empagliflozin, Other SGLT2 inhibitors, Other non-insulin GLDs
- Where
- Germany
- Volunteers
- 31,908 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Empa PASS on Urinary Tract Malignancies
The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor.
- Trial name
- NCT03464045
- Testing
- empagliflozin, DPP-4 inhibitors
- Where
- 3 sites in Finland, Sweden and 1 more
- Volunteers
- 344,995 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes Mellitus
Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
Single-center, prospective, active-controlled, open, randomized, 2 arm parallel, interventional, exploratory pilot Type 2 diabetic patients with high cardiovascular risks who have inadequate glycaemic control with metformin-based…
- Trial name
- NCT02964572
- Testing
- Glimepiride, Empagliflozin
- Where
- South Korea
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Type 2 Diabetes Mellitus
Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy
The purpose of this studay is to compare the efficacy of different hypoglycemic regimens versus twice-daily premixed insulin in type 2 diabetes mellitus (T2DM) patients after short-term ntensive Insulin Therapy by using…
- Trial name
- NCT05545800
- Testing
- metformin+empagliflozin+insulin glargine, IDegLira, premixed insulin analogues
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Xiangya Hospital of Central South University
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2 Without Complication
Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes
To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness parameters measured by carotid-femoral pulse wave velocity.
- Trial name
- NCT05109949
- Testing
- Dapagliflozin 10Mg Tab, Empagliflozin 25 MG
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico